Trial · NCT02137759
MRSI to Predict Response to RT/TMZ ± Belinostat in GBM
NCT02137759, Phase 2, Completed, Emory University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. MRSI to Predict Response to RT/TMZ ± Belinostat in GBM. Trials, record NCT02137759. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02137759
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- MRSI to Predict Response to RT/TMZ ± Belinostat in GBM
- NCT number
- NCT02137759
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 29 participants, actual
- Lead sponsor
- Emory University
- Conditions
- Glioblastoma Multiforme of Brain
- Interventions
- Standard Radiation Therapy, Standard Temozolomide, Belinostat
- First posted
- 2014-05-14
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression Free Survival (PFS) | From date of registration to date of progression or death | The investigators will use a support vector machine approach to determine an MRSI 5-metabolite profile at week 3 in Cohort 1 that is predictive of prolonged PFS at 9 months. |
| Primary | Maximum Tolerated Dose of Belinostat (Cohort 2a) | 9 weeks | The investigators will determine the maximum tolerated dose of belinostat (up to 1000 mg/day x 5 days q3weeks x 3) used with standard RT/temozolomide for newly diagnosed GBM patients. |
| Secondary | Median Overall Survival | From the date of surgery until death or last known follow-up; median follow-up was 50 months. | Overall survival was defined as the time from the date of surgery until death from any cause. Participants who were alive or lost to follow-up were censored at their last known follow-up. Median overall survival was estimated using the Kaplan-Meier method. |
| Secondary | Progression Free Survival | From date of registration to date of progression or death | The investigators will determine whether changes in MRSI metabolite maps at day 8 (for Cohort 2 only) and week 11 (for Cohort 1 and 2) predict for PFS at 9 months. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants4
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|---|---|---|---|---|---|
| P30CA138292 | Winship Cancer Institute Cancer Center Support Grant | RAMALINGAM, SURESH S | EMORY UNIVERSITY | NATIONAL CANCER INSTITUTE | 2009 to 2025 | NIH RePORTER |
| F30CA206291 | Towards the automation of MR spectroscopic imaging in patients with glioblashoma | GURBANI, SAUMYA | EMORY UNIVERSITY | NATIONAL CANCER INSTITUTE | 2016 to 2020 | NIH RePORTER |
| R21NS100244 | Development of automated web-based spectroscopic MRI clinical interface | SHIM, HYUNSUK; COOPER, LEE; SCHREIBMANN, EDUARD | EMORY UNIVERSITY | NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE | 2017 | NIH RePORTER |
| U01CA172027 | Quantitative MRSI to predict early response to SAHA therapy in new GBM management | SHIM, HYUNSUK; BARKER, PETER B; HU, XIAOPING P; OLSON, JEFFREY J; SHU, HUI-KUO | EMORY UNIVERSITY | NATIONAL CANCER INSTITUTE | 2013 to 2017 | NIH RePORTER |
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02137759
GET https://conductscience.org/api/trials/v1/NCT02137759/registered